New model aims to cure hepatitis c in homeless drug users
NCT ID NCT07667101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The goal is to see if this approach increases the number of people who get evaluated and cured of hepatitis C.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Direct-acting antivirals (DAAs) for hepatitis C, plus PrEP for HIV and naloxone for overdose prevention, delivered through a pharmacist-led collaborative care model
What this could lead to
If successful, this model could cure hepatitis C in a hard-to-reach population, reducing liver disease and preventing spread of the virus.
What could go wrong
This is an implementation study, not a drug trial. Success depends on engagement and follow-up, which can be challenging in this population. The cure rate may be lower than in controlled settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C (HCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harborview Medical Center
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••